Inhibition of foamy virus reverse transcriptase by human immunodeficiency virus type 1 RNase H inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4086-4093

  Corona, Angela ^a   Schneider, Anna ^b   Schweimer, Kristian ^b   Rösch, Paul ^b   Wöhrl, Birgitta M ^b   Tramontano, Enzo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FOAMY VIRUS REVERSE TRANSCRIPTASE; RDS 1643; RIBONUCLEASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; 6-(1-(4-FLUOROPHENYL)METHYL-1H-PYRROL-2-YL)-2,4-DIOXO-5-HEXENOIC ACID ETHYL ESTER; BETA-THUJAPLICIN; HEXANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE INHIBITOR; TERPENE; TROPOLONE;

ALPHA HELIX; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; IC 50; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE; SPUMAVIRUS; X RAY CRYSTALLOGRAPHY;

ANTI-HIV AGENTS; CAPROATES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR DOCKING SIMULATION; MONOTERPENES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PYRROLES; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H; SPUMAVIRUS; TROPOLONE;

EID: 84903163606     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00056-14     Document Type: Article

References (41)

1. Rinke CS, Boyer PL, Sullivan MD, Hughes SH, Linial ML. 2002. Mutation of the catalytic domain of the foamy virus reverse transcriptase leads to loss of processivity and infectivity. J. Virol. 76:7560-7570. http://dx.doi.org/10.1128/ JVI.76.15.7560-7570.2002. (Pubitemid 34760979)
2. Boyer PL, Stenbak CR, Clark PK, Linial ML, Hughes SH. 2004. Characterization of the polymerase and RNase H activities of human foamy virus reverse transcriptase. J. Virol. 78:6112-6121. http://dx.doi.org/10.1128/JVI.78. 12.6112-6121.2004. (Pubitemid 38715909)
3. Hartl MJ, Mayr F, Rethwilm A, Wöhrl BM. 2010. Biophysical and enzymatic properties of the simian and prototype foamy virus reverse transcriptases. Retrovirology 7:5. http://dx.doi.org/10.1186/1742-4690-7-5.
4. Hartl MJ, Wöhrl BM, Rösch P, Schweimer K. 2008. The solution structure of the simian foamy virus protease reveals a monomeric protein. J. Mol. Biol. 381:141-149. http://dx.doi.org/10.1016/j.jmb.2008.05.064.
5. Hartl MJ, Bodem J, Jochheim F, Rethwilm A, Rösch P, Wöhrl BM. 2011. Regulation of foamy virus protease activity by viral RNA: a novel and unique mechanism among retroviruses. J. Virol. 85:4462-4469. http://dx.doi.org/10.1128/JVI.02211-10.
6. Goff SP. 2007. Retroviridae: The retroviruses and their replication, p 1999-2069. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
7. Leo B, Hartl MJ, Schweimer K, Mayr F, Wöhrl BM. 2012. Insights into the structure and activity of prototype foamy virus RNase H. Retrovirology 9:14. http://dx.doi.org/10.1186/1742-4690-9-14.
8. Leo B, Schweimer K, Rösch P, Hartl MJ, Wöhrl BM. 2012. The solution structure of the prototype foamy virus RNase H domain indicates an important role of the basic loop in substrate binding. Retrovirology 9:73. http://dx.doi.org/10.1186/1742-4690-9-73.
9. Evans DB, Brawn K, Deibel MR, Jr, Tarpley WG, Sharma SK. 1991. A recombinant ribonucleaseHdomain of HIV-1 reverse transcriptase that is enzymatically active. J. Biol. Chem. 266:20583-20585. (Pubitemid 21908502)
10. Hostomsky Z, Hostomska Z, Hudson GO, Moomaw EW, Nodes BR. 1991. Reconstitution in vitro of RNase H activity by using purified N-terminal and C-terminal domains of human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 88:1148-1152. http://dx.doi.org/10.1073/pnas. 88.4.1148. (Pubitemid 21916182)
11. Smith JS, Gritsman K, Roth MJ. 1994. Contributions of DNA polymerase subdomains to the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 68:5721-5729. (Pubitemid 24258587)
12. Esposito F, Corona A, Tramontano E. 2012. HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions. Mol. Biol. Int. 2012:586401. http://dx.doi.org/10.1155/2012/586401.
13. Tramontano E. 2006. HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target. Mini Rev. Med. Chem. 6:727-737. http://dx.doi.org/10.2174/138955706777435733. (Pubitemid 43881124)
14. Tramontano E, Di Santo R. 2010. HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development. Curr. Med. Chem. 17:2837-2853. http://dx.doi.org/10.2174/092986710792065045.
15. Distinto S, Maccioni E, Meleddu R, Corona A, Alcaro S, Tramontano E. 2013. Molecular aspects of the RT/drug interactions. Perspective of dual inhibitors. Curr. Pharm. Des. 19:1850-1859. http://dx.doi.org/10.2174/ 1381612811319100009.
16. Rausch JW. 2013. Ribonuclease inhibitors: structural and molecular biology, p 143-172. In Le Grice SFJ, GotteM(ed), Human immnodeficiency virus reverse transcriptase. A bench-to-bedside success. Springer, London, United Kingdom.
17. Himmel DM, Maegley KA, Pauly TA, Bauman JD, Das K, Dharia C, Clark AD, Jr, Ryan K, Hickey MJ, Love RA, Hughes SH, Bergqvist S, Arnold E. 2009. Structure of HIV-1 reverse transcriptase with the inhibitor beta-thujaplicinol bound at the RNase H active site. Structure 17:1625-1635. http://dx.doi.org/10. 1016/j.str.2009.09.016.
18. Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, McCoy-Simandle K, Ilina T, Clark AD, Jr, Knight JL, Julias JG, Clark PK, Krogh-Jespersen K, Levy RM, Hughes SH, Parniak MA, Arnold E. 2006. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem. Biol. 1:702-712. http://dx.doi.org/10.1021/cb600303y.
19. Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, Chen X, Eisenberg EJ, Jin W, Kutty N, Leavitt S, Liclican A, Liu Q, Liu X, Mak J, Perry JK, Wang M, Watkins WJ, Lansdon EB. 2009. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J. Med. Chem. 52:5781-5784. http://dx.doi.org/10.1021/jm900597q.
20. Lansdon EB, Liu Q, Leavitt SA, Balakrishnan M, Perry JK, Lancaster-Moyer C, Kutty N, Liu X, Squires NH, Watkins WJ, Kirschberg TA. 2011. Structural and binding analysis of pyrimidinol carboxylic acid and N -hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob. Agents Chemother. 55: 2905-2915. http://dx.doi.org/10.1128/AAC.01594-10.
21. Su HP, Yan Y, Prasad GS, Smith RF, Daniels CL, Abeywickrema PD, Reid JC, Loughran HM, Kornienko M, Sharma S, Grobler JA, Xu B, Sardana V, Allison TJ, Williams PD, Darke PL, Hazuda DJ, Munshi S. 2010. Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J. Virol. 84:7625-7633. http://dx.doi.org/10.1128/JVI. 00353-10.
22. Pari K, Mueller GA, DeRose EF, Kirby TW, London RE. 2003. Solution structure of the RNaseHdomain of the HIV-1 reverse transcriptase in the presence of magnesium. Biochemistry 42:639-650. http://dx.doi.org/10.1021/bi0204894. (Pubitemid 36133288)
23. Christen MT, Menon L, Myshakina NS, Ahn J, Parniak MA, Ishima R. 2012. Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. Chem. Biol. Drug Des. 80:706-716. http://dx.doi.org/10.1111/cbdd.12010.
24. Gong Q, Menon L, Ilina T, Miller LG, Ahn J, Parniak MA, Ishima R. 2011. Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem. Biol. Drug Des. 77:39-47. http://dx.doi.org/10.1111/j.1747- 0285.2010.01052.x.
25. Stahl SJ, Kaufman JD, Vikić-Topić S, Crouch RJ, Wingfield PT. 1994. Construction of an enzymatically active ribonucleaseHdomain of human immunodeficiency virus type 1 reverse transcriptase. Protein Eng. 7:1103-1108. http://dx.doi.org/10.1093/protein/7.9.1103. (Pubitemid 24282496)
26. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, Danzeisen R, Olsen DB, Carroll SS, Embrey M, Wai JS, Miller MD, Cole JL, Hazuda DJ. 2003. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino) thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278:2777-2780. http://dx.doi.org/10.1074/jbc.C200621200. (Pubitemid 36801178)
27. Davies JF, Jr, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA. 1991. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase Science 252:88 -95. http://dx.doi.org/10.1126/science.1707186.
28. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 2005. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res. 65:117-124. http://dx.doi.org/10.1016/j.antiviral.2004.11.002. (Pubitemid 40222288)
29. Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31:455-461.
30. Suchaud V, Bailly F, Lion C, Tramontano E, Esposito F, Corona A, Christ F, Debyser Z, Cotelle P. 2012. Development of a series of 3-hydroxyquinolin- 2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity. Bioorg. Med. Chem. Lett. 22:3988-3992. http://dx.doi.org/10. 1016/j.bmcl.2012.04.096.; http://dx.doi.org/10.1016/j.bmcl.2012.04.096.
31. Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, Rausch JW, Wilson JA, Beutler JA, Thomas CJ, Arnold E, Le Grice SF. 2011. Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. J. Med. Chem. 54:4462-4473. http://dx.doi.org/10.1021/jm2000757.
32. Chung S, Wendeler M, Rausch JW, Beilhartz G, Gotte M, O'Keefe BR, Bermingham A, Beutler JA, Liu S, Zhuang X, Le Grice SF. 2010. Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H. Antimicrob. Agents Chemother. 54:3913-3921. http://dx.doi.org/ 10.1128/AAC.00434-10.
33. Distinto S, Esposito F, Kirchmair J, Cardia MC, Gaspari M, Maccioni E, Alcaro S, Markt P, Wolber G, Zinzula L, Tramontano E. 2012. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. Eur. J. Med. Chem. 50:216-229. http://dx.doi.org/10.1016/j.ejmech.2012.01.056.
34. Esposito F, Sanna C, Del Vecchio C, Cannas V, Venditti A, Corona A, Bianco A, Serrilli AM, Guarcini L, Parolin C, Ballero M, Tramontano E. 2013. Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities. Pathog. Dis. 68:116-124. http://dx.doi.org/10.1111/2049-632X.12051.
35. Esposito F, Corona A, Zinzula L, Kharlamova T, Tramontano E. 2012. New anthraquinone derivatives as inhibitors of the HIV-1 reverse transcriptase-associated ribonucleaseHfunction. Chemotherapy 58:299-307. http://dx.doi.org/10.1159/000343101.
36. Esposito F, Kharlamova T, Distinto S, Zinzula L, Cheng YC, Dutschman G, Floris G, Markt P, Corona A, Tramontano E. 2011. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. FEBS J. 278:1444-1457. http://dx.doi.org/10. 1111/j.1742-4658.2011.08057.x.
37. Chung S, Miller JT, Johnson BC, Hughes SH, Le Grice SF. 2012. Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. J. Biol. Chem. 287:4066-4075. http://dx.doi.org/10.1074/jbc.M111.314781.
38. Ren J, Stammers DK. 2008. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 134:157-170. http://dx.doi.org/10.1016/j.virusres.2007.12.018.
39. Yu SF, Baldwin DN, Gwynn SR, Yendapalli S, Linial ML. 1996. Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science 271: 1579 -1582. http://dx.doi.org/10.1126/science.271. 5255.1579.
40. Yu SF, Sullivan MD, Linial ML. 1999. Evidence that the human foamy virus genome is DNA. J. Virol. 73:1565-1572. (Pubitemid 29036812)
41. Rethwilm A. 2010. Molecular biology of foamy viruses. Med. Microbiol. Immunol. 199:197-207. http://dx.doi.org/10.1007/s00430-010-0158-x.